PEG-talazoparib (PLX376) / ProLynx - LARVOL DELTA

Long-Acting Poly(ADP-ribose) Polymerase Inhibitor Prodrug for Humans. (PubMed, Bioconjug Chem) - "From several possibilities, we chose two conjugates that could be administered intravenously every 2 weeks and maintain TLZ within its known therapeutic window. We describe situations where the PEG∼TLZ conjugates would find utility in humans and suggest how the intravenously administered long-acting prodrugs could in fact be more effective than daily oral administration of free TLZ."

Journal • Oncology • BRCA

Incremental Gains Toward Better Outcomes in Small Cell Lung Cancer (THE ASCO POST) - "'The benefit was modest, and in my opinion, additional studies are warranted in better understanding biomarker testing in SCLC, including SLFN11,' said Dr. Leal. Further analysis of the biomarker data may reveal signals for differential benefits, according to Dr. Leal. 'I think this study highlighted that we can start selecting patients based on biomarkers-realizing that small cell lung cancer is not a 'one-size-fits-all' kind of disease and that we need to strategize treatment in a more rational way,' she added."

Biomarker • Media quote

The Benefit of the Addition of Talazoparib to Enzalutamide in First Line Treatment for mCRPC TALAPRO-2 - Neeraj Agarwal (Urotoday) - "Neeraj Agarwal joins...to discuss the TALAPRO-2 phase 3 trial, evaluating the combination of the PARP inhibitor talazoparib and enzalutamide versus enzalutamide and placebo as first-line treatment in patients with metastatic castration-resistant prostate cancer (mCRPC)."

Video